A single priming dose of tremelimumab plus Imfinzi every four weeks reduced risk of death by 22% in HIMALAYA Phase III trialCombination also showed no increase in severe liver toxicity and fewer discontinuations due to treatment-related adverse events vs. sorafenib

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 18 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2022 22:11:10 UTC.